Literature DB >> 34503991

Differential Susceptibilities of Catecholamines to Metabolism by Monoamine Oxidases.

David S Goldstein1, Genessis Castillo2, Patti Sullivan2, Yehonatan Sharabi2.   

Abstract

The endogenous catecholamines dopamine (DA), norepinephrine (NE), and epinephrine (EPI) play key roles in neurobehavioral, cardiovascular, and metabolic processes; various clinical disorders; and effects of numerous drugs. Steps in intracellular catecholamine synthesis and metabolism were delineated long ago, but there remains a knowledge gap. Catecholamines are metabolized by two isoforms of monoamine oxidase (MAO), MAO-A and MAO-B, and although the anatomic localization of MAO-A and MAO-B and substrate specificities of enzyme inhibitors are well characterized, relative susceptibilities of the endogenous catecholamines to enzymatic oxidation by MAO-A and MAO-B have not been studied systematically. MAOs catalyze the conversion of catecholamines to catecholaldehydes-3,4-dihydroxyphenylacetaldehyde (DOPAL) from DA and 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) from NE and EPI. In this study we exploited the technical ability to assay DOPAL and DOPEGAL simultaneously with the substrate catecholamines to compare DA, NE, and EPI in their metabolism by MAO-A and MAO-B. For both MAO isoforms, DA was the better substrate compared to NE or EPI, which were metabolized equally. Since catecholaminergic neurons express mainly MAO-A, the finding that MAO-A is more efficient than MAO-B in metabolizing endogenous catecholamines reinforces the view that the predominant route of intraneuronal enzymatic oxidation of catecholamines is via MAO-A. The results have implications for clinical neurochemistry, experimental therapeutics, and computational models of catecholaminergic neurodegeneration. For instance, the greater susceptibility of DA than the other catecholamines to both MAO isoforms can help explain relatively high concentrations of the deaminated DA metabolite 3,4-dihydroxyphenylacetic acid than of the NE metabolite 3,4-dihydroxyphenylglycol in human plasma and urine. SIGNIFICANCE STATEMENT: Endogenous catecholamines are metabolized by monoamine oxidase (MAO)-A and -B, yielding the catecholaldehydes 3,4-dihydroxyphenylacetaldehyde (DOPAL) from dopamine (DA) and 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) from norepinephrine (NE) and epinephrine (EPI). Based on measurements of DOPAL and DOPEGAL production, DA is a better substrate than NE or EPI for both MAO isoforms, and MAO-A is more efficient than MAO-B in metabolizing DA, NE, and EPI. MAO-A is the main route of intraneuronal metabolism of endogenous catecholamines. U.S. Government work not protected by U.S. copyright.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34503991      PMCID: PMC9164308          DOI: 10.1124/jpet.121.000826

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.402


  26 in total

1.  TYROSINE HYDROXYLASE. THE INITIAL STEP IN NOREPINEPHRINE BIOSYNTHESIS.

Authors:  T NAGATSU; M LEVITT; S UDENFRIEND
Journal:  J Biol Chem       Date:  1964-09       Impact factor: 5.157

2.  Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry.

Authors:  J Saura; Z Bleuel; J Ulrich; A Mendelowitsch; K Chen; J C Shih; P Malherbe; M Da Prada; J G Richards
Journal:  Neuroscience       Date:  1996-02       Impact factor: 3.590

3.  Sympathetic nervous function in human heart as assessed by cardiac spillovers of dihydroxyphenylglycol and norepinephrine.

Authors:  G Eisenhofer; M D Esler; I T Meredith; A Dart; R O Cannon; A A Quyyumi; G Lambert; J Chin; G L Jennings; D S Goldstein
Journal:  Circulation       Date:  1992-05       Impact factor: 29.690

Review 4.  Selective inhibitors of monoamine oxidase type B and the "cheese effect".

Authors:  John P M Finberg; Ken Gillman
Journal:  Int Rev Neurobiol       Date:  2011       Impact factor: 3.230

5.  Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.

Authors:  I Lamensdorf; M B Youdim; J P Finberg
Journal:  J Neurochem       Date:  1996-10       Impact factor: 5.372

Review 6.  Norrie disease and MAO genes: nearest neighbors.

Authors:  Z Y Chen; R M Denney; X O Breakefield
Journal:  Hum Mol Genet       Date:  1995       Impact factor: 6.150

7.  PC12 cells as a window for the differentiation of neural crest into adrenergic nerve ending and adrenal medulla.

Authors:  M B Youdim
Journal:  J Neural Transm Suppl       Date:  1991

8.  Human norepinephrine metabolism. Its evaluation bydministration of tritiated norepinephrine.

Authors:  S E Gitlow; M Mendlowitz; L M Bertani; S Wilk
Journal:  J Clin Invest       Date:  1971-04       Impact factor: 14.808

9.  Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease.

Authors:  David S Goldstein; Courtney Holmes; Grisel J Lopez; Tianxia Wu; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2018-02-15       Impact factor: 4.891

10.  Re-assessing the catecholamine hypothesis of depression: the case of melancholic depression.

Authors:  Philip W Gold; Ma-Li Wong
Journal:  Mol Psychiatry       Date:  2021-05-12       Impact factor: 15.992

View more
  2 in total

Review 1.  Natural Products Inhibitors of Monoamine Oxidases-Potential New Drug Leads for Neuroprotection, Neurological Disorders, and Neuroblastoma.

Authors:  Narayan D Chaurasiya; Francisco Leon; Ilias Muhammad; Babu L Tekwani
Journal:  Molecules       Date:  2022-07-04       Impact factor: 4.927

2.  Citicoline/Coenzyme Q10/Vitamin B3 Fixed Combination Exerts Synergistic Protective Effects on Neuronal Cells Exposed to Oxidative Stress.

Authors:  Leonardo Mastropasqua; Luca Agnifili; Claudio Ferrante; Matteo Sacchi; Michele Figus; Gemma Caterina Maria Rossi; Lorenza Brescia; Raffaella Aloia; Giustino Orlando
Journal:  Nutrients       Date:  2022-07-20       Impact factor: 6.706

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.